Looks like we will get a good indication of how trial is going. Very interesting.
Emerging Role of Blood Biomarkers in TBI Clinical Trials: Initial Findings from the Phase II INTREPID2566 Trial
The multicenter INTREPID-2566 trial investigates the safety and efficacy of NNZ-2566 in patients with traumatic brain injury (TBI). Circulating brain damage markers are being evaluated as potential indicators of drug efficacy, as well as to improve characterization and stratification of trial participants and to identify possible molecular mechanisms of the drug. Dr. Mondello will outline our initial findings from the first cohort of moderate to severe TBI patients.
Results will be presented characterizing the simultaneous assessment of 3 pathobiologically diverse biomarkers at the time of admission and at various stages during the evolution of TBI. The rationale and potential of new multimarker strategies for TBI clinical trials to overcome substantial injury-specific and inter-individual pathophysiological heterogeneity and to identify patients who are most likely to benefit from specific drug treatment will be discussed. In addition, implications for biomarker use in regulatory decision-making will be outlined.
NEU Price at posting:
9.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)